Watch ALZN. Know when insiders buy.
One email the day a filing lands. Free.
Work order
75
PASS · insiders 50, shorts 100
Insiders, 90 days
−$3K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$8.8MNET CASH —52W 0.86 – 2.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Apr 30derived | — | — | — | −$2.9M | −$2.9M | — | -0.74 | −$2.8M | — | — | Jul 22 |
| Q3 2026 · Jan 31 | — | — | — | −$2.2M | −$2.2M | — | -0.58 | −$1.7M | — | — | Mar 11 |
| Q2 2026 · Oct 31 | — | — | — | −$998K | −$1M | — | -0.30 | −$1.2M | — | — | Dec 9 |
| Q1 2026 · Jul 31 | — | — | — | −$2.7M | −$2.7M | — | -1.28 | −$2.4M | — | — | Sep 10 |
| Q4 2025 · Apr 30derived | — | — | — | −$1.1M | −$1.1M | — | -1.78 | −$689K | — | — | Jul 22 |
| Q3 2025 · Jan 31 | — | — | — | −$1M | −$1M | — | -1.75 | −$1.4M | — | — | Mar 11 |
| Q2 2025 · Oct 31 | — | — | — | −$1.4M | −$1.4M | — | -3.61 | −$3.4M | — | — | Dec 9 |
| Q1 2025 · Jul 31 | — | — | — | −$962K | −$974K | — | -11.42 | −$1.1M | — | — | Sep 10 |
| Q4 2024 · Apr 30derived | — | — | — | −$850K | −$852K | — | -118.81 | −$1.4M | — | — | Jul 22 |
| Q3 2024 · Jan 31 | — | — | — | −$2.7M | −$2.7M | — | -3.77 | −$2M | — | — | Mar 10 |
| Q2 2024 · Oct 31 | — | — | — | −$2.9M | −$2.9M | — | -4.43 | −$1.5M | — | — | Dec 11 |
| Q1 2024 · Jul 31 | — | — | — | −$3.5M | −$3.5M | — | -5.38 | −$3.3M | — | — | Sep 11 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Apr 30 | — | — | −$8.8M | −$8.8M | — | -2.63 | −$8.1M | — | — | — | — |
| FY2025 · to Apr 30 | — | — | −$4.5M | −$4.5M | — | -11.32 | −$6.6M | — | — | — | — |
| FY2024 · to Apr 30 | — | — | −$9.9M | −$9.9M | — | -132.33 | −$8.3M | — | — | — | — |
| FY2023 · to Apr 30 | — | — | −$14.9M | −$14.9M | — | -22.89 | −$8.9M | — | — | — | — |
| FY2022 · to Apr 30 | — | — | −$12.3M | −$12.4M | — | -0.14 | −$6.6M | — | — | — | — |
| FY2021 · to Apr 30 | — | — | −$5M | −$5M | — | -0.07 | −$2.7M | — | — | — | — |
Every number comes from Alzamend Neuro, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.